Evidence map›Paper›PMID 38822266›Full record

ArticleBMC gastroenterology2024

Development and validation of a 13-item short version of the inflammatory bowel disease self-efficacy scale.

Makoto Tanaka, Aki Kawakami, Kayoko Sakagami, Tomoko Terai, Jovelle Fernandez, Laurie Keefer, Hiroaki Ito

Abstract readValidation Study
In one paragraph

Article in BMC gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Makoto TanakaGraduate School of Health Care Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. hmakoto-tky@umin.ac.jp.
Aki KawakamiGraduate School of Health Care Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Kayoko SakagamiKinshukai Infusion Clinic, Osaka, Japan.
Tomoko TeraiJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Jovelle FernandezJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Laurie KeeferIcahn School of Medicine at Mount Sinai, New York City, NY, USA.
Hiroaki ItoKinshukai Infusion Clinic, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe inflammatory bowel disease self-efficacy scale (IBD-SES) is an instrument used across many countries to measure important health outcomes of patients with inflammatory bowel disease (IBD). We aimed to develop and validate a substantially shorter version of this scale to reduce patients' response burden.

methodsA total of 919 patients with IBD, 482 recruited from an IBD clinic and 437 recruited online, completed the Japanese version of the original, 29-item IBD-SES. These data were then used to develop a shorter version of the scale. The original 29 items of the IBD-SES were reduced with three analytic steps: assessing ceiling and floor effect, testing correlation between items, and assessing test-retest reliability. The resulting 13-item IBD-SES was evaluated for construct validity by confirmatory factor analysis, criterion validity by Pearson correlation coefficients with original version, and internal consistency by item-total correlations and the Cronbach's α coefficient.

resultsThe short version consisted of the same four subscales "managing stress and emotions," "managing medical care," "managing symptoms and disease," and "maintaining remission" as the original scale. The fit indices of the final model were as follows: normed chi-square, 7.18 (p < 0.001); comparative fit index, 0.94; goodness-of-fit index, 0.93; adjusted goodness-of-fit index, 0.89; parsimony goodness-of-fit index, 0.60; and root mean square error of approximation, 0.084. Correlation of each subscale with the original scale was high (0.97-0.98). Cronbach's α for each subscale ranged from 0.68 to 0.86.

conclusionsA short version of the IBD-SES was developed. The results confirmed the improved validity, reliability, and psychometric properties of the IBD-SES.

trial registrationNot applicable.

Indexed as

Inflammatory Bowel DiseasesPsychometricsSelf EfficacyAdultAgedFactor Analysis, StatisticalFemaleHumansJapanMaleMiddle AgedReproducibility of ResultsSurveys and QuestionnairesYoung AdultInflammatory bowel diseasePatient-reported outcome measuresSelf-efficacy

Identifiers

PMID38822266
PMCPMC11141053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.